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Pleiotropic Effects of CSF Levels of Alzheimer’s
Disease Proteins
Background & Motivation

Methods

Our method is gene- or region-based. What makes it stand apart is the fact that a genetic
Cerebrospinal fluid (CSF) analytes harbor potential as diagnostic biomarkers
for Alzheimer’s Disease (AD). Quantitative measures of CSF proteins comprise a region serves as an outcome in the model, not a predictor (i.e., the so-called reverse regression).
APOE Gene
set of often highly correlated endophenotypes that have previously shown promise
in genetic analyses (Cruchaga et al., 2013; Kauwe et al., 2014). Pleiotropic impact of genetic variations on this set may provide additional insights into AD
The genetic information does not enter the
pathology at its earliest stages. To determine which specific endophenotypes are
model as discretized allele counts (e.g., 0, 1, 2)
pleiotropic, one can employ methods based on the reverse regression of genotype
but rather as a smooth function G(t), with t inon phenotypes. Recently, we proposed a method based on functional linear models
dexing a genetic variants’ position over a genetic
(Vsevolozhskaya et al, 2016) that utilizes reverse regression and simultaneously
region.
evaluates all variants within a genetic region for an association with multiple corFig. 1 illustrates genotypic functions fitted for
related phenotypes. Here we apply our novel methodology to explore pleiotropic
each subject, G (t),  = 1, . . . 309, over the
eff ects of CSF analtyes using Alzheimer’s Disease Neuroimaging Initiative (ADNI)
APOE region.
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Smoothed allele counts within the APOE region for 309
subjects.
Figure 1:

CSF levels of β-amyloid (Aβ) and τ proteins are potentially early diagnostic Statistical Analysis
markers for probable AD. We investigated the influence of genetic variation on
To examine the effect of SNPs on the 2 CSF biomarkers, we fit the following functional linear
these markers for two candidate genes: APOE and CLU.
model:
Data were obtained from the ADNI database. A total of 309 (AD = 79, MCI
E [G (t)] = β0 (t) + β1 (t)XT + β2 (t)XAbet + β3 (t)Xε4
= 148, NL = 82) individuals were included.
P3
526 APOE single nucleotide polymorphism (SNP) and 569 CLU SNPs were
β4 (t)XSe + β5 (t)XAge + β6 (t)XDg + j=1 β6+j (t)XPCj .
available for the analysis.
Normal (n = 82)
Age (year)
CSF Aβ levels (pg/ml)
CSF tau levels (pg/ml)
Male
Female
Table 1:

Mean MCI (n = 148) Mean AD (n = 79) Mean
75.0
74.4
74.3
205.5
161.9
144.9
70.5
102.1
120.7
N
N
N
45
101
44
37
47
35

Demogphic, clinical and biomarker data for ADNI subjects.

The model is looking for an association with a CSF biomarker, while adjusting for the level of
the other protein, gender, age and diagnosis status. Also, to ensure the significance is not due to
population stratification, we incorporated the top three principal components to further control
for the population structure.
Two analyses were performed: with APOE ε4 genotype (number of APOE ε4 alleles; 0, 1,
2) as a covariate and without.
The analysis is Bayesian; the estimated β̂j (t)’s are obtained as posterior expectations; the
confidence bands are obtained as 95% posterior crediable intervals.

Results: Exploring the estimated β̂T (t) and β̂Abet (t)
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Estimated posterior expectation of APOE association with
Aβ biomarker and the corresponding 95% credible intervals.
Figure 2:

APOE: ε4 adjustment

0.10

Cervantes et al., 2011, tested APOE
rs79429216 and rs76214972 for an association with AD, but after multiple test
correction their allelic P-value were found
to be non-significant (0.747 and 0.053 respectively). Nonetheless, in our analysis,
the credible interval for the genetic effect
of both of these SNPs does not capture
zero and they were found to be associated
with the elevated τ levels.
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Allele dosage

APOE genotype is the established risk
factor for LOAD. The two previously identified APOE SNPs (rs429358, rs7412)
that define the ε2/ ε3/ ε4 alleles for AD
susceptibility are among the top SNPs
that drive the association with the elevated Aβ levels in our model. Additionally, TOMM40/APOE rs7254892 that
was recently identified to be associated
with longer human longevity (Lin et al.,
2016) is clearly associated with lower Aβ
levels in our analysis. TOMM40/APOE
rs2075650 is also associated with lower
Aβ levels under the functional inference,
confirming prior report by Kim et al.,
2011.
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Estimated posterior expectation of APOE association with τ
biomarker and the corresponding 95% credible intervals.
Figure 3:

CLU gene
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Estimated posterior expectation of CLU association with Aβ biomarker, τ biomarker and the corresponding 95% credible
intervals.

Figure 5:
Figure 4:

Estimated posterior expectation over APOE after ε4 covariate adjustment.

The ε4 adjustment did not have a significant impact on the association between
τ levels and AD; for Aβ the region over APOE SNPs rs429358, rs7412 is not longer
significant. Nonetheless, the second interval still contains a statistically significant signal

No CLU SNPs were found to be associated with Aβ levels
Two markers (rs7012010, rs7012217) are in the constellation of SNPs that are associated with the elevated τ levels. Both of these SNPs were previously reported

